KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GSK) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $3.0 billion.

  • Gsk's Cost of Revenue fell 219.21% to $3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $20.0 billion, marking a year-over-year increase of 562.74%. This contributed to the annual value of $11.6 billion for FY2024, which is 856.53% up from last year.
  • Per Gsk's latest filing, its Cost of Revenue stood at $3.0 billion for Q3 2025, which was down 219.21% from $2.9 billion recorded in Q2 2025.
  • In the past 5 years, Gsk's Cost of Revenue ranged from a high of $11.6 billion in Q4 2024 and a low of $2.3 billion during Q1 2021
  • For the 5-year period, Gsk's Cost of Revenue averaged around $4.1 billion, with its median value being $2.9 billion (2022).
  • In the last 5 years, Gsk's Cost of Revenue tumbled by 7570.81% in 2021 and then soared by 19849.58% in 2022.
  • Gsk's Cost of Revenue (Quarter) stood at $3.8 billion in 2021, then soared by 198.5% to $11.2 billion in 2022, then decreased by 5.14% to $10.6 billion in 2023, then rose by 9.24% to $11.6 billion in 2024, then crashed by 73.77% to $3.0 billion in 2025.
  • Its last three reported values are $3.0 billion in Q3 2025, $2.9 billion for Q2 2025, and $2.4 billion during Q1 2025.